Cure8 research brief
This small case series suggests upadacitinib may induce and maintain steroid-free remission in some UC patients after tofacitinib failure, a potential option for people with refractory disease.
Adults with UC who failed tofacitinib or multiple prior therapies; gastroenterologists; researchers interested in JAK inhibitor sequencing.
This small single-centre retrospective case series from a Canadian tertiary hospital reports outcomes for nine adult ulcerative colitis patients who switched to upadacitinib after losing response to tofacitinib.
Eight patients completed induction therapy with upadacitinib; four achieved steroid-free clinical remission during maintenance with supporting endoscopic and histologic improvement. The authors note durable remission beyond one year in those four patients.
Single-centre retrospective series of nine patients; limited sample size and study design mean findings are preliminary. Source content is an abstract/partial extraction.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing...
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...
